Grace Experts Cited in Pharma’s Almanac Q3 2021 Round Table
Grace experts across our pharmaceutical portfolio were recently asked to contribute their thoughts to a digital round table discussion hosted by Pharma’s Almanac.
What do you think most differentiates the U.S. pharma/biopharma industry or the market?
Grace’s Dave Short, Global Business & Technology Manager, Fine Chemicals responded:
“Innovation, reliability, and transparency are some of the biggest differentiators when it comes to the U.S. pharma/biopharma industry. The number and percentage of new chemical or biological entities developed in the United States continues to grow both in terms of total numbers and percentage breakdown relative to other regions. Additionally, core areas of the United States continue to be hubs for development of new technologies.
Reliability and transparency are crucial in an industry focused on safely and efficiently saving lives and improving health.
As a key supplier into the industry, these are aspects that Grace has long embodied and are integral to our core model and the value we deliver to our clients.”
Read all contributor responses here.
With major investment in our manufacturing facilities, Grace is well prepared to meet an increased demand for silica gel. Grace also is working on technologies for the purification of mRNA, and we are committed to bolstering collaborations with pharma companies.
President, Materials Technologies
What’s the next “big thing” on the horizon that will significantly alter the pharma/biopharma market, your operations, or the way you do business?
Grace’s Sandra Wisniewski, President, Materials Technologies and Reno Nguyen, Principal Scientist answered:
“From the perspective of some of our pharma customers, mRNA will be the biggest focus for the next generation vaccines for influenza, yellow fever, HIV, etc.; and new therapies for cystic fibrosis, multiple sclerosis, and different types of cancer. Of course, mRNA technology cannot work without lipids, which stabilize and ensure delivery of the nucleic acid molecules within human cells. Grace chromatographic silicas will become increasingly important for the purification of the key lipids.
With major investment in our manufacturing facilities, Grace is well prepared to meet an increased demand for silica gel. Grace also is working on technologies for the purification of mRNA, and we are committed to bolstering collaborations with pharma companies.”
Read all contributor responses here.
About Pharma’s Almanac
Since its inception in 2015, Pharma’s Almanac has grown into a premier publication, a Nice Insight publication increasingly recognized for offering in-depth analysis of pharma’s most intensive markets, active business sectors and major players. To provide readers a point of engagement for those looking for primary market research or decision-supporting business data and commentary, the industry’s newest magazine is now posting the best of its business, thought leadership and technical trend content online. pharmasalmanac.com